SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000950170-23-008148
Filing Date
2023-03-15
Accepted
2023-03-15 16:18:08
Documents
93
Period of Report
2022-12-31

Document Format Files

Seq Description Document Type Size
1 10-K qncx-20221231.htm   iXBRL 10-K 4157089
2 EX-23.1 qncx-ex23_1.htm EX-23 3979
3 EX-31.1 qncx-ex31_1.htm EX-31 17371
4 EX-31.2 qncx-ex31_2.htm EX-31 16824
5 EX-32.1 qncx-ex32_1.htm EX-32 14406
6 EX-32.2 qncx-ex32_2.htm EX-32 13590
  Complete submission text file 0000950170-23-008148.txt   15708203

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT qncx-20221231.xsd EX-101.SCH 73819
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT qncx-20221231_def.xml EX-101.DEF 310920
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT qncx-20221231_cal.xml EX-101.CAL 67361
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT qncx-20221231_pre.xml EX-101.PRE 498420
11 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT qncx-20221231_lab.xml EX-101.LAB 635830
87 EXTRACTED XBRL INSTANCE DOCUMENT qncx-20221231_htm.xml XML 3615990
Mailing Address 601 GATEWAY BOULEVARD, SUITE 1250 SOUTH SAN FRANCISCO CA 94080
Business Address 601 GATEWAY BOULEVARD, SUITE 1250 SOUTH SAN FRANCISCO CA 94080 415-910-5717
Quince Therapeutics, Inc. (Filer) CIK: 0001662774 (see all company filings)

IRS No.: 901024039 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-38890 | Film No.: 23735425
SIC: 2836 Biological Products, (No Diagnostic Substances)